| Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma C Raggi, ML Taddei, E Sacco, N Navari, M Correnti, B Piombanti, ... Journal of hepatology 74 (6), 1373-1385, 2021 | 91 | 2021 |
| Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma F Tovoli, V Dadduzio, S De Lorenzo, L Rimassa, G Masi, M Iavarone, ... Liver Cancer 10 (4), 370-379, 2021 | 41 | 2021 |
| Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy V Burgio, M Iavarone, GG Di Costanzo, F Marra, S Lonardi, E Tamburini, ... Cancer Management and Research, 9379-9389, 2021 | 38 | 2021 |
| Prevalence of nutritional risk and malnutrition during and after hospitalization for COVID-19 infection: Preliminary results of a single-centre experience C Fiorindi, F Campani, L Rasero, C Campani, L Livi, L Giovannoni, ... Clinical nutrition ESPEN 45, 351-355, 2021 | 31 | 2021 |
| Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab C Campani, J Bamba‐Funck, B Campion, S Sidali, L Blaise, ... Liver International 43 (3), 708-717, 2023 | 30 | 2023 |
| Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients M Persano, M Rimini, T Tada, G Suda, S Shimose, M Kudo, J Cheon, ... European Journal of Cancer 189, 112933, 2023 | 29 | 2023 |
| Hepatectomy versus sorafenib in advanced nonmetastatic hepatocellular carcinoma: a real-life multicentric weighted comparison S Famularo, M Donadon, F Cipriani, F Giuliante, S Ferri, C Celsa, ... Annals of Surgery 275 (4), 743-752, 2022 | 29 | 2022 |
| Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study Q Zeng, C Klein, S Caruso, P Maille, DS Allende, B Mínguez, M Iavarone, ... The Lancet Oncology 24 (12), 1411-1422, 2023 | 28 | 2023 |
| Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: a validated prediction model F Vizzutti, C Celsa, V Calvaruso, M Enea, S Battaglia, L Turco, M Senzolo, ... Hepatology 77 (2), 476-488, 2023 | 27 | 2023 |
| REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study A Casadei-Gardini, M Rimini, M Kudo, S Shimose, T Tada, G Suda, ... Liver Cancer 11 (6), 527-539, 2022 | 26 | 2022 |
| Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice E Desjonqueres, C Campani, F Marra, J Zucman‐Rossi, JC Nault Liver International 42 (3), 492-506, 2022 | 23 | 2022 |
| The protease‐inhibitor SerpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma M Correnti, A Cappon, M Pastore, B Piombanti, G Lori, DVPN Oliveira, ... Liver International 42 (1), 233-248, 2022 | 23 | 2022 |
| Genetics of hepatocellular carcinoma: from tumor to circulating DNA C Campani, J Zucman-Rossi, JC Nault Cancers 15 (3), 817, 2023 | 21 | 2023 |
| Pattern of macrovascular invasion in hepatocellular carcinoma M Guarino, A Cucchetti, G Pontillo, F Farinati, F Benevento, GL Rapaccini, ... European Journal of Clinical Investigation 51 (7), e13542, 2021 | 21 | 2021 |
| Multifaceted aspects of metabolic plasticity in human cholangiocarcinoma: an overview of current perspectives M Pastore, G Lori, A Gentilini, ML Taddei, G Di Maira, C Campani, ... Cells 9 (3), 596, 2020 | 21 | 2020 |
| Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma IG Rapposelli, S Shimose, T Kumada, S Okamura, A Hiraoka, ... ESMO open 6 (4), 100190, 2021 | 19 | 2021 |
| Long‐term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real‐life experience from a tertiary referral center G Dragoni, S Bagnoli, M Le Grazie, C Campani, F Rogai, N Manetti, ... Journal of digestive diseases 20 (5), 235-242, 2019 | 19 | 2019 |
| Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab W Limousin, P Laurent-Puig, M Ziol, N Ganne-Carrié, P Nahon, ... Journal of hepatology 79 (6), 1450-1458, 2023 | 18 | 2023 |
| Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib IG Rapposelli, T Tada, S Shimose, V Burgio, T Kumada, H Iwamoto, ... Liver International 41 (12), 2997-3008, 2021 | 18 | 2021 |
| Extracellular signal‐regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells A Gentilini, G Lori, A Caligiuri, C Raggi, G Di Maira, M Pastore, ... Hepatology 74 (4), 2007-2020, 2021 | 14 | 2021 |
